Related Experiment Videos

[Serotonin reuptake inhibitors in children. Warnings on the administration, results analysis, and recommendations]

J M Fegert1, B Herpertz-Dahlmann

  • 1Universitätsklinik für Kinder- und Jugendpsychiatrie/Psychotherapie, Ulm. joerg.fegert@medizin.uni-ulm.de

Der Nervenarzt
|September 1, 2005
PubMed

Insights

Serotonin reuptake inhibitors (SSRI) are not recommended for treating depression in individuals under 18 due to increased suicide-related behavior risk. Combining SSRI with cognitive behavioral therapy may mitigate this risk in depressed youth.

Area of Science:

  • Psychiatry
  • Developmental Psychopharmacology
  • Pediatric Mental Health

Context:

  • Regulatory authorities worldwide advise against new use of SSRI for pediatric depression.
  • Concerns exist regarding increased suicide-related behavior risk in adolescents on SSRI.
  • No completed suicides were reported in the studies reviewed.

Purpose:

  • To provide clinical practice recommendations for SSRI use in children and adolescents.
  • To address the contraindication of SSRI for new-onset depressive illness in pediatric patients.
  • To synthesize current data on SSRI risks and benefits in youth.

Summary:

  • SSRI are generally contraindicated for treating depression in individuals under 18.
  • Regulatory agencies like EMEA and BfArM recommend caution.
  • Combining SSRI with psychological treatments, such as CBT, may reduce suicidal behavior risk.

Impact:

  • Informs clinical decision-making for pediatric psychopharmacology.
  • Guides healthcare providers on SSRI prescription for adolescents.
  • Highlights the importance of integrated treatment approaches for youth depression.

Related Concept Videos

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...